Skip to main content
. 2020 Jan 14;4:60. Originally published 2019 Apr 1. [Version 2] doi: 10.12688/wellcomeopenres.14769.2

Table 3. Summary of costs and benefits, 2017–2030.

Scenarios compared Total cost (USD) Estimated clinical
cases averted		 Deaths averted Economic benefits
(USD)		 Incremental
cost (USD)		 ROI
Business as usual
vs. elimination (with
resistance assumption)		 29.024 billion
(range: 23.64–36.23)		 123.14 million
(estimated) 4


16.54 million
(reported) 5 		386,167
(estimated)


193,084
(reported)		 87.73 billion
(range: 26.3–347.14)		 14.05 billion 6:1
Business as usual vs.
elimination (baseline)		 28.953 billion
(range: 23.38–35.72)
92.23 million
(estimated clinical)


11.68 million
(reported) 		264,322
(estimated clinical)


132,161
(reported)		 72.90 billion 13.79 billion 5:1
Reverse vs. elimination
(with resistance
assumption)		 NA 845.73 million 3.487 million N/A 6.693 billion N/A